

The SmartPak™ Pharmacy

Dog & Cat Product Information Sheet

Vetmedin® Chewable Tablets

Common Drug Name – Pimobendan

How Supplied by SmartPak – Vetmedin is available in 1.25mg and 5mg strengths in 50-count bottles.

Category – Vetmedin is a vasodilator that also increases the strength of muscular contractions in the heart (positive inotrope).

Caution - Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indications (Uses) – For the management of the signs of mild, moderate or severe congestive heart failure (CHF) in dogs due to atrioventricular valvular insufficiency (AVVI) or dilated cardiomyopathy (DCM).

Dosage and Administration – Vetmedin should be administered orally at a total daily dose of 0.23mg/lb body weight, using a suitable combination of whole or half tablets. The total daily dose should be divided into 2 portions that are not necessarily equal, and the portions should be administered approximately 12 hours apart (ie morning and evening).

Contraindications – Vetmedin should not be given in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical conditions where augmenting cardiac output is inappropriate.

Precautions – The safety of Vetmedin has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than AVVI or DCM. The safe use of Vetmedin has not been evaluated in dogs younger than 6 months, dogs with congenital heart defects, dogs with diabetes mellitus or other

serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches.

Human Warning – Not for human use. Keep out of reach of children. Consult a physician in case of accidental ingestion.

Warning – Only for use in dogs with clinical evidence of heart failure. At 3 and 5 times the recommended dosage administered over a 6-month period of time, pimobendan caused an exaggerated hemodynamic response in the normal dog heart, which was associated with cardiac pathology.

Adverse Reactions (Side Effects) –Adverse reactions/clinical findings were recorded in a 56-day field study of dogs with CHF. Dogs were treated with either Vetmedin or the active control enalapril maleate. Adverse reactions/clinical findings were seen in both treatment groups with the same prevalence and were potentially related to CHF, the therapy, or both: poor appetite (38%), lethargy (33%), diarrhea (30%), dyspnea (29%), azotemia (14%), weakness and ataxia (13%), pleural effusion (10%), syncope (9%), cough (7%), sudden death (6%), ascites (6%), and heart murmur (3%).

Storage Conditions: Store at room temperature, between 59 and 86F.

Manufactured for:
Boehringer Ingelheim Vetmedica, Inc.
St. Joseph, MO 64506

Rev. 11/08

SmartPak
40 Grissom Road, Suite 500
Plymouth, MA 02360
Phone: 1-800-431-4194
Fax: 1-800-431-4179
www.SmartPak.com